Evidence at a glance.
Each therapy is rated by the strength of clinical evidence — from large human trials down to primarily preclinical research. Ratings are educational; a licensed provider decides what may be appropriate for you.
Large Human Trials
A GLP-1 receptor agonist commonly evaluated for medical weight management and metabolic support.
Dual GIP/GLP-1 receptor agonist evaluated for weight and cardiometabolic health.
GHRH analog with FDA approval for a specific HIV-related indication; sometimes discussed off-label.
Multiple Human Studies
GHRH analog studied for stimulation of the body's own growth hormone.
GHRH and GHRP combination studied for pulsatile growth hormone release.
Coenzyme central to cellular energy, sirtuin activation, and DNA-repair pathways.
Endogenous tripeptide antioxidant used clinically in select settings.
Melanocortin receptor agonist with an FDA-approved indication in premenopausal women; other uses discussed with providers.
Immunomodulatory peptide studied for T-cell function.
Small Human Studies
Copper-binding tripeptide studied for skin and hair follicle signaling.
Neuroendocrine peptide studied in hypothalamic-pituitary-gonadal signaling.
Modified GH fragment studied for lipolysis in research settings.
Mitochondrial-derived peptide studied in metabolic homeostasis research.
Neuropeptide sometimes discussed for mood, bonding, and intimacy support in provider-directed protocols.
Orally active ghrelin receptor agonist studied for GH/IGF-1 secretion.